Olmesartan worsening known thrombocytopenia. A rare side effect of antihypertensive drugs

Hellenic J Cardiol. 2017 Jan-Feb;58(1):96-97. doi: 10.1016/j.hjc.2017.01.020. Epub 2017 Feb 3.

Authors

Elias A Sanidas¹, Georgios Tzanis², Dimitris Papadopoulos², John Barbetseas², Vasilios Papademetriou³

Affiliations

¹ ESH Center of Excellence for Hypertension, Dept. of Cardiology, "Laiko" General Hospital, Athens, Greece. Electronic address: [email protected].
² ESH Center of Excellence for Hypertension, Dept. of Cardiology, "Laiko" General Hospital, Athens, Greece.
³ Hypertension and Cardiovascular Research Clinic, Veterans Affairs and Georgetown University Medical Centers, Washington DC, USA.

PMID: 28163153
DOI: 10.1016/j.hjc.2017.01.020

No abstract available

Keywords: Drug-induced thrombocytopenia; Myelodysplastic syndrome; Olmesartan.

Publication types

Case Reports
Letter

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Aftercare
Aged
Antihypertensive Agents / adverse effects*
Antihypertensive Agents / therapeutic use
Bone Marrow / pathology
Humans
Hypertension / drug therapy*
Imidazoles / adverse effects*
Imidazoles / therapeutic use
Intracranial Hemorrhages / diagnostic imaging*
Intracranial Hemorrhages / etiology
Male
Myelodysplastic Syndromes / chemically induced
Myelodysplastic Syndromes / complications
Myelodysplastic Syndromes / pathology*
Tetrazoles / adverse effects*
Tetrazoles / therapeutic use
Thrombocytopenia / chemically induced*
Thrombocytopenia / drug therapy
Tomography, X-Ray Computed / methods
Treatment Outcome

Substances

Adrenal Cortex Hormones
Antihypertensive Agents
Imidazoles
Tetrazoles
olmesartan